Wells Fargo analyst Derek Archila raised the firm’s price target on Ascendis Pharma (ASND) to $330 from $322 and keeps an Overweight rating on the shares. The firm notes management’s EUR 500M OCF guide excluding CNP implies EUR 1.1B-ERU 1.2B for Yorvipath and consistent with Ascendis’ commentary of EUR 40M-EUR 50M in revenue growth quarter-over-quarter last week.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ASND:
- Ascendis Pharma: Sustained Commercial Momentum and TransCon Pipeline Catalysts Underpin Buy Rating
- Ascendis Pharma Grants New Employee Warrants, Updates Articles of Association
- Ascendis Pharma: Vision 2030 Growth Story Driven by Yorvipath and Late‑Stage TransCon Pipeline Justifies Buy Rating
- Ascendis Pharma price target raised to $246 from $242 at BofA
- Ascendis Pharma Sets 2026 Milestones and Unveils $120 Million Share Buyback